Neon Therapeutics

We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.

At Neon we are committed to advancing the field of cancer immunotherapy by investing in research in neoantigen biology, epitope prediction, cancer bioinformatics, personalized therapies and advanced immune profiling of cancer patients.

Headquartered in Cambridge, MA., Neon Therapeutics is a private company launched in 2015 with $55 million in Series A venture capital financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.

Type
Private
HQ
Cambridge, US
Founded
2015
Employees
48 (est)+5%
Neon Therapeutics was founded in 2015 and is headquartered in Cambridge, US

Neon Therapeutics Locations

Cambridge, US

Neon Therapeutics Metrics

Neon Therapeutics Summary

Founding Date

2015

Total Funding

$125 M

Latest funding size

$70 M

Time since last funding

17 days

Investors

We estimate that Neon Therapeutics's latest funding round in January 2017 was $70 M. In total, Neon Therapeutics has raised $125 M

Neon Therapeutics News

Neon Therapeutics Company Life

You may also be interested in